BioMS and Lilly discontinue dirucotide after Phase III trial fails
This article was originally published in Scrip
Executive Summary
BioMS and Lilly have discontinued the development programme of their potential multiple sclerosis therapy dirucotide after it failed to meet the primary endpoint of a two-year Phase III trial in secondary progressive MS.